Executive SummaryThe valuation of early-stage Healthcare AI companies in Europe presents a complex yet highly opportune landscape. These nascent ventures, often operating in pre-revenue phases, contend with prolonged development cycles and intricate regulatory frameworks. Despite these challenges, the sector is experiencing significant growth, fuelled by escalating M&A activity, robust investor confidence in AI’s transformative capabilities, […]
